Cargando…

Efficacy of Postoperative Hormone Replacement Therapy on Prognosis of Patients with Serous Ovarian Carcinoma

BACKGROUND: Ovarian cancer is the most common cause of gynecological cancer-associated death. Iatrogenic menopause might adversely affect the quality of life and health outcomes in young female cancer survivors. We evaluated whether postoperative hormone replacement therapy (HRT) had a negative infl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yong-Li, Chen, Jin-Hong, Lu, Wen, Li, Bi-Lan, Zhu, Qin-Yi, Wan, Xiao-Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4894042/ https://www.ncbi.nlm.nih.gov/pubmed/27231169 http://dx.doi.org/10.4103/0366-6999.182835

Ejemplares similares

Hormone Receptors in Serous Ovarian Carcinoma: Prognosis, Pathogenesis, and Treatment Considerations
por: Voutsadakis, Ioannis A.
Publicado: (2016)

Age is associated with prognosis in serous ovarian carcinoma
por: Deng, Fei, et al.
Publicado: (2017)

Postoperative Hormone Replacement Therapy and Survival in Women with Ovarian Cancer
por: Ji, Eunjeong, et al.
Publicado: (2022)

Significance of TEAD Family in Diagnosis, Prognosis and Immune Response for Ovarian Serous Carcinoma
por: Ren, Xinxin, et al.
Publicado: (2021)

Overexpression of CUEDC2 Predicts Poor Prognosis in Ovarian Serous Carcinomas
por: Wang, Aichun, et al.
Publicado: (2015)

High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma
por: Cui, Xuelian, et al.
Publicado: (2015)

Identification of metastasis and prognosis-associated genes for serous ovarian cancer
por: Yang, Yijun, et al.
Publicado: (2020)

Identification of Prognosis Biomarkers for High-Grade Serous Ovarian Cancer Based on Stemness
por: Wang, Zhihang, et al.
Publicado: (2022)

Proteomic Discovery of Biomarkers to Predict Prognosis of High-Grade Serous Ovarian Carcinoma
por: Kim, Se Ik, et al.
Publicado: (2020)

A 4-gene signature predicts prognosis of uterine serous carcinoma
por: Chen, Hui, et al.
Publicado: (2021)

Expression and molecular profiles of the AlkB family in ovarian serous carcinoma
por: Cai, Yuan, et al.
Publicado: (2021)

Hormone receptor expression profiles differ between primary and recurrent high-grade serous ovarian cancers
por: Feng, Zheng, et al.
Publicado: (2017)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

The Role of Mesothelin Expression in Serous Ovarian Carcinoma: Impacts on Diagnosis, Prognosis, and Therapeutic Targets
por: Giordano, Giovanna, et al.
Publicado: (2022)

Differential expression of argininosuccinate synthetase in serous and non‐serous ovarian carcinomas
por: Cheon, Dong‐Joo, et al.
Publicado: (2014)

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas
por: Sadlecki, Pawel, et al.
Publicado: (2018)

Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells
por: Dey, Puja, et al.
Publicado: (2022)

A clinically applicable molecular classification for high-grade serous ovarian cancer based on hormone receptor expression
por: Feng, Zheng, et al.
Publicado: (2016)

Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC)
por: Feng, Zheng, et al.
Publicado: (2017)

Comprehensive analysis of the expression of sodium/potassium-ATPase α subunits and prognosis of ovarian serous cystadenocarcinoma
por: Huang, Wei, et al.
Publicado: (2020)

EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma
por: Chen, Xiao, et al.
Publicado: (2016)

Lysophosphatidic Acid-Induced Transcriptional Profile Represents Serous Epithelial Ovarian Carcinoma and Worsened Prognosis
por: Murph, Mandi M., et al.
Publicado: (2009)

MDCT-Based Radiomics Features for the Differentiation of Serous Borderline Ovarian Tumors and Serous Malignant Ovarian Tumors
por: Yu, Xin-ping, et al.
Publicado: (2021)

Morphological and molecular basis of ovarian serous carcinoma
por: Rosen, Daniel G, et al.
Publicado: (2010)

Architectural Histopathological Changes in Ovarian Serous Carcinomas
por: DOCHIȚ, C., et al.
Publicado: (2018)

A Comprehensive Review of Ovarian Serous Carcinoma
por: Hatano, Yuichiro, et al.
Publicado: (2019)

Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer
por: Feng, Li-yuan, et al.
Publicado: (2021)

Proteomic Discovery of Plasma Protein Biomarkers and Development of Models Predicting Prognosis of High-Grade Serous Ovarian Carcinoma
por: Kim, Se Ik, et al.
Publicado: (2023)

Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis
por: Li, Jie, et al.
Publicado: (2012)

Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan
por: Kang, Jun-Hyeok, et al.
Publicado: (2020)

Differences between primary peritoneal serous carcinoma and advanced serous ovarian carcinoma: a study based on the SEER database
por: Li, Xiaoduo, et al.
Publicado: (2021)

A case of synchronous serous ovarian cancer and uterine serous endometrial intraepithelial carcinoma
por: Shimizu, Maho, et al.
Publicado: (2021)

Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma
por: Norris, Eric J, et al.
Publicado: (2019)

Gene Expression Subtyping Reveals Immune alterations:TCGA Database for Prognosis in Ovarian Serous Cystadenocarcinoma
por: Feng, Chunxia, et al.
Publicado: (2021)

Lipid Droplet Accumulation Independently Predicts Poor Clinical Prognosis in High-Grade Serous Ovarian Carcinoma
por: Iwahashi, Naoyuki, et al.
Publicado: (2021)

Stem Cell-Associated Signatures Help to Predict Diagnosis and Prognosis in Ovarian Serous Cystadenocarcinoma
por: Li, Li, et al.
Publicado: (2023)

Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression
por: Cheasley, Dane, et al.
Publicado: (2022)

Impaired FHIT expression characterizes serous ovarian carcinoma
por: Ozaki, K, et al.
Publicado: (2001)

Oxidatively Modified Proteins in the Serous Subtype of Ovarian Carcinoma
por: Mehrabi, Sharifeh, et al.
Publicado: (2014)

Acrokeratosis paraneoplastica in serous ovarian carcinoma: case report
por: Hempen, Aline, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_c6diljp91ghs4hhkn67p8celu4